Valeant (VRX) Makes $5.7B Bid for Cephalon (CEPH)
Tweet
Share
E-mail
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) has made a $73 per share bid for Cephalon, Inc. (Nasdaq: CEPH).
Total value on the deal is $5.7 billion.
Valeant announced its intention to commence a consent solicitation process during the week of April 4th in an effort to replace Cephalon's current Board of Directors with its own nominees. Valeant anticipates that the transaction will be entirely debt financed.
Total value on the deal is $5.7 billion.
Valeant announced its intention to commence a consent solicitation process during the week of April 4th in an effort to replace Cephalon's current Board of Directors with its own nominees. Valeant anticipates that the transaction will be entirely debt financed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Holcim to acquire Fermacell from James Hardie for EUR 840M
- T. Rowe Price to acquire F/m Investments in fixed income push
- CoStar Group acquires Zonda for $800M, adding new home data
Create E-mail Alert Related Categories
Hot M&A, Mergers and Acquisitions, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
